Fewer Than Half of Accelerated Approval Drugs Demonstrated Benefit Within 5 Years – The ASCO Post
A study by Liu et al presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract 918) investigating whether cancer drugs granted accelerated approval by the FDA ultimately demonstrated clinical benefit has found that only 43% of the drugs showed benefit in terms of overall survival or quality of life within 5 years of accelerated approval in confirmatory trials. Patients should be clearly informed about the many cancer drugs that use the accelerated approval process—and